Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Go back to Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.13 +0.02 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.11 | 52 Week High | $18.00 | |||
| Open | $5.09 | 52 Week Low | $6.91 | |||
| Day High | $5.15 | P/E | N/A | |||
| Day Low | $5.04 | EPS | $-0.67 | |||
| Volume | 1,658,567 | |||||
